The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Valuation Is Forecasted For The Zika Virus Therapeutics Market By 2030 Starting From Its 2026 Size?
The zika virus therapeutics market size has seen strong expansion in recent years. It is forecast to increase from $32.06 billion in 2025 to $34 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.0%. The past growth can be attributed to several factors, including historical outbreaks in endemic regions, a reliance on symptomatic treatment approaches, the expansion of public health monitoring systems, the development of basic diagnostic tools, and heightened awareness of congenital zika complications.
The zika virus therapeutics market is anticipated to experience substantial expansion over the upcoming years. By 2030, this market is projected to reach $42.49 billion, exhibiting a compound annual growth rate (CAGR) of 5.7%. This forecasted growth is primarily driven by factors such as enhanced investments in infectious disease research, a heightened demand for preventive vaccines, the broadening of global disease surveillance networks, an increased emphasis on maternal health protection, and intensified collaboration among public health agencies. Significant trends during this period are expected to encompass a greater focus on antiviral drug development, increased investment in vaccine research initiatives, the expansion of supportive care therapeutics, enhanced surveillance of vector-borne diseases, and improved public health preparedness.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21323&type=smp
What Major Growth Drivers Are Shaping The Outlook Of The Zika Virus Therapeutics Market?
The projected high incidence rate of infection is poised to drive the expansion of the Zika virus therapeutics market going forward. An infection rate represents the probability or risk of an infection occurring within a specific population during a defined period. This incidence of infection stems from factors such as inadequate vector control, environmental conditions favorable for mosquito breeding, and limited access to preventive healthcare in affected regions. The prevalence of infection mandates effective Zika virus therapeutics, fostering the development of and investment in vaccines and treatments to combat the escalating public health threat. For instance, in December 2024, the UK Health Security Agency, a UK-based government organization, reported around eight confirmed cases of the Zika virus between January and June 2024, showing a 700% increase in incidence compared to the same period in 2023. Therefore, the increasing incidence rate of infection will stimulate the growth of the Zika virus therapeutics market.
Which Segment Categories Define The Zika Virus Therapeutics Market?
The zika virus therapeutics market covered in this report is segmented –
1) By Product: Acetaminophen, Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
2) By Vaccine Type: Inactivated Vaccine, Subunit Vaccine, Live-Attenuated Vaccine, Other Vaccine Types
3) By End User: Hospitals, Clinics, Other End Users
Subsegments:
1) By Acetaminophen: Oral Tablets, Oral Suspensions, Intravenous Formulations
2) By Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Aspirin, Naproxen, Celecoxib
What Industry Trends Are Redefining The Zika Virus Therapeutics Market?
Leading companies within the zika virus therapeutics market are prioritizing the creation of advanced technologies, including second-generation adjuvanted inactivated vaccines, to improve immune response, boost vaccine efficacy, and deliver more enduring protection against the virus. A second-generation adjuvanted inactivated vaccine integrates a deactivated virus with an immune-enhancing adjuvant to amplify the body’s immune reaction, providing superior defense against the intended disease. As an illustration, in March 2024, Valneva SE, a biotechnology company based in France known for vaccine manufacturing, declared the start of Phase 1 clinical trials for VLA1601. This is a highly purified inactivated vaccine candidate targeting Zika virus (ZIKV), developed using the identical manufacturing platform as Valneva’s approved Japanese encephalitis vaccine, IXIARO. The vaccine’s formulation includes an adjuvant, which contains substances designed to bolster the immune response, a crucial factor for its effectiveness.
Who Are The Top Companies Competing In The Zika Virus Therapeutics Market?
Major companies operating in the zika virus therapeutics market are Johnson & Johnson, Merck & Co Inc, Sanofi S A, Takeda Pharmaceutical Company Limited, Moderna Inc, Emergent BioSolutions Inc, Valneva SE, Bharat Biotech International Limited, Inovio Pharmaceuticals Inc, GeoVax Labs Inc, GlaxoSmithKline plc, Novavax Inc, Pfizer Inc, GeneOne Life Science Inc, Zydus Cadila, Indian Immunologicals Limited, Enesi Pharma, Protein Sciences Corporation, Sementis Ltd, Hawaii Biotech Inc, GeneOne Life Science
Read the full zika virus therapeutics market report here:
https://www.thebusinessresearchcompany.com/report/zika-virus-therapeutics-global-market-report
Which Regions Are Projected To Dominate The Zika Virus Therapeutics Market In The Coming Years?
North America was the largest region in the zika virus therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the zika virus therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Zika Virus Therapeutics Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=21323&type=smp
Browse Through More Reports Similar to the Global Zika Virus Therapeutics Market 2026, By The Business Research Company
Antiviral Combination Therapy Global Market Report
https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report
Oncolytic Virus Therapy Global Market Report
https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report
Antivirals Global Market Report
https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model